sipuleucel-T

{
  "id": "MLC-T-ONC-007788",
  "term": "sipuleucel-T",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A vaccine used to treat prostate cancer that has spread to other parts of the body. It is used in patients who have few or no symptoms and whose cancer is castration resistant (has not responded to treatments that lower testosterone levels). Sipuleucel-T is made from a patient’s immune cells that have been treated in the laboratory with GM-CSF (a type of growth factor) and a protein found on prostate cancer cells. Sipuleucel-T may help the immune system kill prostate cancer cells. It is a type of autologous cellular immunotherapy and a type of dendritic cell vaccine. Also called APC 8015 and Provenge.",
    "A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP."
  ],
  "synonyms": [
    "APC 8015",
    "Provenge",
    "APC8015 vaccine",
    "PA2024 (PAP/GM-CSF)-loaded dendritic cell vaccine",
    "SipT"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/sipuleucel-t/"
}